SMART research

ContactContact ConsultantOrganizer
China Insights Consultancy
China Insights ConsultancyChina Insights Consultancy (CIC) is headquartered in Shanghai, with offices in Hong Kong, Nanjing, Beijing, and Hangzhou, and branches in Shenzhen and Guangzhou. The current staff size has exceeded 300 people. CIC is a professional consulting firm serving corporate investment, financing and strategic development, providing comprehensive industry consulting and advisory services for companies in various industries to go public and finance on the capital market. It has helped numerous Chinese companies successfully go public overseas. At the same time, we provide comprehensive business due diligence services for private equity funds investing in China, helping them to discover real opportunities and avoid potential risks. In 2021, CIC ranked first among industry advisors in the Hong Kong and US IPO markets, completing IPO projects for leading companies including Li Auto, KE Holdings, Tuya, Didi, Baidu, Weibo, etc., and has extensive project experience in new energy and the circular economy. CIC’s projects are highly customized and it is the only industry consultant in the market that has completed GDR projects, with a deep understanding of the GDR service process. CIC has long-term cooperation with numerous buy-side funds and investment groups and brings a strong buy-side perspective to reflect a company’s investment value in industry reports. CIC has been established for over a decade. Rooted in China and serving clients globally, it upholds the philosophy of “letting knowledge create value” and provides professional, reliable consulting services. Its research covers nearly 1,000 sub-sectors, with consulting experience for more than 3,000 enterprises, and a database linking over 1,000,000 senior industry experts. CIC also provides comprehensive commercial due diligence and expert network services for private equity funds investing in China and other emerging markets. By leveraging diversified online and offline research methods and expert engagement, CIC helps clients obtain first-hand information to support investment and business decisions.
Categories
01China
02Consulting Services
03Life Sciences
Jun 29, 202302:07:37
SMART research
0:00
0:00
/
0:00
Details

At this year's Euro PCR 2023, the results of two percutaneous renal artery denervation (RDN) studies from China were presented in the "Late Breaking Clinical Trail" session, which aroused heated debates in both academia and the industry: one of them is the "Pivotal Trial of Targeted Denervation for Hypertension" led by Professor Huo Yong of Peking University First Hospital and supported by Suzhou Xinmai Medical Device Co. (hereinafter referred to as "SMART Trial") led by Prof. Huo Yong from Peking University First Hospital and supported by Suzhou Xinmai Medical Devices Co. Ltd. (hereinafter referred to as "Miliweiye") supported the clinical trial "Effectiveness and Safety Study of Netrod-HTN Radiofrequency Denervation System". Both trials received considerable attention, and the results of the studies were positive, providing new evidence for the treatment of hypertension with RDN. The results were deemed positive because, based on the data reported by the investigators, both clinical trials met both the primary and secondary objectives of the study hypotheses. Based on the data reported by the two trials at the conference, on 29 June 2023, industry consultant CIC Consulting led the successful online live streaming of the "SMART Trial Results Interpretation Conference". The meeting was hosted by CIC Consulting, which provided an excellent sharing and interpretation of the differences between the two trials, from protocol design to clinical implementation to data collection, which are worth exploring and thinking about in depth.